Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLK2 Recombinant Protein (Active & Pro-enzyme Forms) High purity (>95%), Endotoxin <1EU/μg, Sequence Verified. HEK293 expressed for native glycosylation. |
View KLK2 Products |
| Gene Delivery | KLK2 ORF Lentivirus Full-length ORF for stable cell line construction and secretion studies. |
View KLK2 Products |
| Benchmark Ab | Anti-KLK2 Monoclonal Antibody (Sequence of Clinical Benchmarks) Recombinant positive control for binding and competition assays. |
View KLK2 Products |
| Validator | KLK2 siRNA Set (3 unique sequences) For knockdown verification and target engagement confirmation. |
View KLK2 Products |
| Related Target A | KLK3 (PSA) Close homolog (80% identity) - Critical for specificity counter-screening. |
View KLK3 Products |
| Related Target B | KLK4 Kallikrein family member; relevant for off-target liability assessment. |
View KLK4 Products |
| Related Target C | FOLH1 (PSMA) Primary synergistic target for prostate cancer profiling and combination therapy. |
View FOLH1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| KLK3 (PSA) Cross-reactivity (80% sequence homology) | KLK2 & KLK3 Ortholog Panel Human/Cyno/Mouse proteins with >95% purity, mass spec verified distinct molecular weights |
| Enzymatic Activity Standardization (Serine protease requires active site titration) | Pre-activated & Zymogen Forms Sequence verified catalytic triad (His57, Asp102, Ser195), >95% purity by SEC-HPLC |
| Subfamily Selectivity Screening (15 kallikreins create off-target potential) | Kallikrein Family Panel KLK2, KLK3, KLK4, KLK11 proteins available for cross-reactivity matrices |
| Internalization Validation (Required for ADC/RLT modality development) | High-Concentration Stock Solutions Low viscosity 10 mg/mL formulations for internalization assays and conjugation chemistry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
| False Positives | Validated siRNA included for cellular specificity checks |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog proteins available with native glycosylation (HEK293 expressed) |
Live KLK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLK2-targeted therapeutics is intensifying, with major players shifting focus from traditional PSA (KLK3) diagnostics to KLK2 as a distinct therapeutic target for metastatic castration-resistant prostate cancer (mCRPC). As first-generation antibody-drug conjugates and radioligand therapies enter Phase I/II trials, the next wave of R&D is targeting allosteric inhibitors and highly specific small molecules that avoid cross-reactivity with the kallikrein family. Key players include Janssen (J&J) for radioligand therapy, Genentech/Bayer for ADC, and Novartis/Lantheus for imaging and therapy. KLK2 offers tremendous potential for targeted alpha-particle therapy (TAT) and bispecific approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy | Janssen (J&J), Novartis, Lantheus | Prostate Cancer (mCRPC), Imaging & Therapy | Internalization & Affinity (Need high-purity HEK293 Antigens) |
| ADC | Genentech, Bayer, Various Biotechs | mCRPC, Solid Tumors / Prostate | Internalization Assay (Need high-purity active KLK2 for binding affinity determination) |
| Bispecific T-cell Engager | Early-stage pipelines | Advanced Prostate Cancer | Heterodimer Validation (Need Selectivity vs KLK3) |
| Small Molecule Inhibitors | Various Biotech | Benign Prostatic Hyperplasia | Selectivity Assay (Need KLK2 vs KLK3 mutant proteins) |
| Biomarker Assay | Roche, Abbott | Early Detection | Specificity Verification (Need KLK2-specific antibodies vs cross-reactive KLK3 binders) |
Functional Domains & Key Mutations
KLK2 is a serine protease of the Peptidase S1 family (UniProt P20151 domain). It contains a catalytic triad (His57, Asp102, Ser195). Key reported mutations (dbSNP):
- rs6072 (VAR_014164)
- rs198977 (VAR_020178)
- rs60268688 (VAR_061775)
Evidence: UniProt P20151.
Related Targets Cross-Selling Strategy
When developing prostate cancer pipelines, customers often pursue combination therapies or parallel development. Recommended cross-selling targets:
- KLK3 (PSA): Mandatory for counter-screening due to 80% homology.
- KLK4: Involved in resistance mechanisms via compensatory pathways.
- FOLH1 (PSMA): Dual-target or sequential therapy.
- STEAP1: Emerging ADC/TCE target in prostate cancer.
TarMart offers bundled panels (KLK2+PSMA+PSA) with discount to accelerate specificity screening and combination studies.